{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T14:31:20Z","timestamp":1788618680427,"version":"build-2803163510"},"reference-count":62,"publisher":"Wiley","issue":"S7","license":[{"start":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T00:00:00Z","timestamp":1752105600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["dom-pubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>The fixed\u2010ratio combinations (FRCs) of a basal insulin and glucagon\u2010like peptide\u20101 receptor agonist (GLP\u20101 RA), IDegLira (insulin degludec\/liraglutide) and iGlarLixi (insulin glargine\/lixisenatide), offer a once\u2010daily injectable treatment option for adults with type 2 diabetes (T2D), combining complementary mechanisms of action to target both fasting and postprandial hyperglycaemia. While randomized controlled trials have demonstrated their efficacy and safety, real\u2010world evidence (RWE) provides important insights into their effectiveness, tolerability and use across routine clinical practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>This is a narrative review of selected real\u2010world studies assessing the FRCs IDegLira and iGlarLixi in adults with T2D. Studies assessing the use of FRCs to intensify and simplify therapy, as well as their use in special populations such as older adults were reviewed and are summarized.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among individuals inadequately controlled on oral antihyperglycaemic drugs (OADs), basal insulin \u00b1 OADs, or GLP\u20101 RAs, initiation of FRC therapy consistently improved glycaemic outcomes, supported modest weight loss or stability, and was associated with a low risk of hypoglycaemia. FRCs have also been evaluated as a strategy for simplifying complex insulin regimens. Transitions from basal\u2013bolus or premixed insulin to FRCs maintained or improved glycaemic control while reducing total daily insulin dose and injection burden.<\/jats:p>\n                    <jats:p>Evidence in special populations and clinical contexts further supports the utility of FRCs. In older adults, FRC use was associated with reductions in HbA1c and hypoglycaemia risk, along with improvements in treatment satisfaction and functional measures. During Ramadan fasting, iGlarLixi demonstrated favourable glycaemic control, low hypoglycaemia incidence, modest weight loss and high adherence. Studies assessing glycaemic control using continuous glucose monitoring showed improvements in time in range, reductions in time above range and stable time below range, indicating enhanced glycaemic stability without increased risk of hypoglycaemia.<\/jats:p>\n                    <jats:p>Two real\u2010world head\u2010to\u2010head studies comparing IDegLira and iGlarLixi found both FRCs to be effective and well tolerated. IDegLira was associated with greater weight loss and lower insulin dose requirements, while iGlarLixi showed advantages in postprandial glucose control. Both agents demonstrated significant improvements in HbA1c and low rates of hypoglycaemia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Collectively, these real\u2010world studies confirm that FRCs are effective, safe and patient\u2010centred treatment options for adults with T2D. Their simplified dosing, metabolic benefits and favourable safety profiles support their use for both therapy intensification and de\u2010intensification across a broad spectrum of clinical scenarios. These findings reinforce results from randomized controlled trials, providing further confidence in the role of FRCs in contemporary diabetes care.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/dom.16593","type":"journal-article","created":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T10:19:08Z","timestamp":1752142748000},"page":"26-41","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["What is the \u2018real\u2010world\u2019 experience with fixed\u2010ratio combination therapy (insulin +\n                    <scp>GLP<\/scp>\n                    \u20101 receptor agonist) in routine clinical practice? Take\u2010home messages for clinicians regarding key outcomes"],"prefix":"10.1111","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9486-1255","authenticated-orcid":false,"given":"Juan Pablo","family":"Frias","sequence":"first","affiliation":[{"name":"Department of Medicine Charles R Drew University of Medicine and Science  Los Angeles California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,7,10]]},"reference":[{"issue":"1","key":"e_1_2_13_2_1","first-page":"S150","article-title":"9. Pharmacologic approaches to glycemic treatment: standards of Care in Diabetes\u20142025","volume":"48","author":"American Diabetes Association","year":"2025","journal-title":"Diabetes Care"},{"issue":"5","key":"e_1_2_13_3_1","first-page":"417","article-title":"2023 AACE comprehensive type 2 diabetes management algorithm","volume":"29","author":"Garber AJ","year":"2023","journal-title":"Endocr Pract"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.2337\/dci24-0003"},{"issue":"5","key":"e_1_2_13_5_1","first-page":"e72","article-title":"The modern role of basal insulin in advancing therapy in people with type 2 diabetes","volume":"48","author":"Riddle MC","year":"2025","journal-title":"Diabetes Care"},{"key":"e_1_2_13_6_1","volume-title":"Xultophy (Insulin Degludec and Liraglutide) Injection, for Subcutaneous Use [Prescribing Information]","author":"Novo Nordisk","year":"2023"},{"key":"e_1_2_13_7_1","volume-title":"Soliqua (Insulin Glargine and Lixisenatide) Injection, for Subcutaneous Use [Prescribing Information]","author":"Sanofi\u2010Aventis","year":"2023"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-023-03543-z"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-024-03868-3"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-018-0547-5"},{"issue":"2","key":"e_1_2_13_11_1","first-page":"715","article-title":"Clinical implications of IDegLira in patients with varying baseline characteristics: a post hoc analysis of DUAL clinical trials","volume":"10","author":"Philis\u2010Tsimikas A","year":"2019","journal-title":"Diabetes Ther"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-017-0336-6"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12961"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsb1609216"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-1974"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13182"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-020-00850-w"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-060852"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-022-01333-w"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15609"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2022.108132"},{"issue":"20","key":"e_1_2_13_22_1","first-page":"10671","article-title":"IDegLira fixed\u2010ratio combination in the real world: a retrospective observational single\u2010center Italian experience","volume":"24","author":"Di Loreto C","year":"2020","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-024-01564-z"},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15579"},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.14740\/jocmr4995"},{"key":"e_1_2_13_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-024-01593-8"},{"key":"e_1_2_13_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2022.110183"},{"key":"e_1_2_13_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.16161"},{"key":"e_1_2_13_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14844"},{"key":"e_1_2_13_30_1","doi-asserted-by":"publisher","DOI":"10.2337\/ds22-0064"},{"key":"e_1_2_13_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14974"},{"key":"e_1_2_13_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.16075"},{"key":"e_1_2_13_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13340-023-00681-7"},{"key":"e_1_2_13_34_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2022.28.9.958"},{"key":"e_1_2_13_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-021-01128-5"},{"key":"e_1_2_13_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-024-01644-0"},{"key":"e_1_2_13_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15599"},{"key":"e_1_2_13_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.16357"},{"key":"e_1_2_13_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-023-01375-8"},{"key":"e_1_2_13_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-022-01327-8"},{"key":"e_1_2_13_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.numecd.2024.03.023"},{"key":"e_1_2_13_42_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-021-01180-1"},{"key":"e_1_2_13_43_1","doi-asserted-by":"publisher","DOI":"10.5455\/medarh.2022.76.96-100"},{"key":"e_1_2_13_44_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-023-01435-z"},{"issue":"2","key":"e_1_2_13_45_1","first-page":"923","article-title":"Real\u2010world study on the effectiveness and safety of basal insulin IDegLira in type 2 diabetic patients previously treated with multi\u2010injective insulin therapy","volume":"25","author":"Persano M","year":"2021","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"e_1_2_13_46_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-024-01645-z"},{"key":"e_1_2_13_47_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-019-0673-8"},{"key":"e_1_2_13_48_1","doi-asserted-by":"publisher","DOI":"10.1002\/edm2.390"},{"key":"e_1_2_13_49_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-019-00725-9"},{"key":"e_1_2_13_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.112341"},{"key":"e_1_2_13_51_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15027"},{"key":"e_1_2_13_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2025.112119"},{"key":"e_1_2_13_53_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-023-01489-z"},{"key":"e_1_2_13_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsx.2023.102707"},{"key":"e_1_2_13_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2024.111567"},{"key":"e_1_2_13_56_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-024-01642-2"},{"key":"e_1_2_13_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(22)00319-9"},{"key":"e_1_2_13_58_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc23-1520"},{"key":"e_1_2_13_59_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00592-024-02361-7"},{"key":"e_1_2_13_60_1","doi-asserted-by":"publisher","DOI":"10.1177\/19322968221149041"},{"key":"e_1_2_13_61_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.16214"},{"issue":"8","key":"e_1_2_13_62_1","first-page":"2782","article-title":"Comparative efficacy and safety of two fixed ratio combinations in type 2 diabetes mellitus patients previously poorly controlled on different insulin regimens: a multi\u2010centric observational study","volume":"26","author":"Bilic\u2010Curcic I","year":"2022","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"e_1_2_13_63_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12902-023-01282-w"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.16593","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T03:58:19Z","timestamp":1761883099000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.16593"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,10]]},"references-count":62,"journal-issue":{"issue":"S7","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["10.1111\/dom.16593"],"URL":"https:\/\/doi.org\/10.1111\/dom.16593","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1111\/DOM.16593\/v2\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.16593\/v2\/review3","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.16593\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.16593\/v2\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.16593\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.16593\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.16593\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.16593\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.16593\/v1\/review3","asserted-by":"object"}]},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,10]]},"assertion":[{"value":"2025-05-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}